| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shengzhao Hu, Yingli Chen, Shipeng Huang, Min Liu, Ying Liu, Shaofang Huan. Sodium Danshensu protects against oxygen glucose deprivation/reoxygenation-induced astrocytes injury through regulating NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome and tuberous sclerosis complex-2 (TSC2)/mammalian target of rapamycin (mTOR) pathways. Annals of translational medicine. vol 10. issue 20. 2022-11-17. PMID:36388798. |
sodium danshensu protects against oxygen glucose deprivation/reoxygenation-induced astrocytes injury through regulating nod-like receptor pyrin domain containing 3 (nlrp3) inflammasome and tuberous sclerosis complex-2 (tsc2)/mammalian target of rapamycin (mtor) pathways. |
2022-11-17 |
2023-08-14 |
Not clear |
| Molly C McNamara, Aaron M Hosios, Margaret E Torrence, Ting Zhao, Cameron Fraser, Meghan Wilkinson, David J Kwiatkowski, Elizabeth P Henske, Chin-Lee Wu, Kristopher A Sarosiek, Alexander J Valvezan, Brendan D Mannin. Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience. vol 25. issue 11. 2022-11-17. PMID:36388985. |
reciprocal effects of mtor inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. |
2022-11-17 |
2023-08-14 |
Not clear |
| Kate Mowrey, Hope Northrup, Syed Shahrukh Hashmi, David Rodriguez-Buritic. Expanding Our Knowledge of Menstrual Irregularities Reported by Females With Tuberous Sclerosis Complex. Frontiers in reproductive health. vol 4. 2022-10-28. PMID:36303615. |
the purpose of our study is to expand the knowledge regarding intrinsic reproductive dysfunction in females with tsc and to explore the impact of mtor inhibitors (mtori) on menstrual irregularity in the tuberous sclerosis complex (tsc) community. |
2022-10-28 |
2023-08-14 |
Not clear |
| R Balestri, L Rizzoli, A Pedrolli, Sam Urru, G Rech, I Neri, C R Girardelli, M Magnan. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in Tuberous Sclerosis Complex - An Update. Journal of the European Academy of Dermatology and Venereology : JEADV. 2022-10-27. PMID:36300771. |
analysis of current data on the use of topical mtor inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex - an update. |
2022-10-27 |
2023-08-14 |
human |
| Marie Girodengo, Sila K Ultanir, Joseph M Batema. Mechanistic target of rapamycin signaling in human nervous system development and disease. Frontiers in molecular neuroscience. vol 15. 2022-10-13. PMID:36226315. |
mtor signaling has a well-established role in hamartoma syndromes such as tuberous sclerosis complex (tsc) and other mtoropathies. |
2022-10-13 |
2023-08-14 |
human |
| Jingwen Zhan. Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures. Clinical medicine (London, England). vol 22. issue Suppl 4. 2022-10-11. PMID:36220212. |
systematic review of mtor inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures. |
2022-10-11 |
2023-08-14 |
Not clear |
| Sean R Williamson, Ondrej Hes, Kiril Trpkov, Aditi Aggarwal, Abhishek Satapathy, Sourav Mishra, Shivani Sharma, Ankur Sangoi, Liang Cheng, Mahmut Akgul, Muhammad Idrees, Albert Levin, Sudha Sadasivan, Pilar San Miguel Fraile, Joanna Rogala, Eva Comperat, Daniel M Berney, Stela Bulimbasic, Jesse K McKenney, Shilpy Jha, Nakul Y Sampat, Sambit K Mohant. Low-grade oncocytic tumor of the kidney is characterized by genetic alterations of TSC1, TSC2, MTOR, or PIK3CA and consistent GATA3 positivity. Histopathology. 2022-10-08. PMID:36208048. |
recurrent tuberous sclerosis / mtor pathway gene alterations in lot supports its consideration as a distinct morphologic, immunohistochemical, and genetic entity. |
2022-10-08 |
2023-08-14 |
Not clear |
| Minyoung Lee, Eun-Jin Kim, Min-Jee Kim, Mi-Sun Yu. Rapamycin Cannot Reduce Seizure Susceptibility in Infantile Rats with Malformations of Cortical Development Lacking mTORC1 Activation. Molecular neurobiology. 2022-10-04. PMID:36194361. |
however, the efficacy of mtor inhibitors in malformations of cortical dysplasia (mcd) outside of the tuberous sclerosis complex is unknown. |
2022-10-04 |
2023-08-14 |
rat |
| Sreedevi Boggarapu, Steven L Roberds, JoAnne Nakagawa, Eric Beresfor. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database. Orphanet journal of rare diseases. vol 17. issue 1. 2022-09-14. PMID:36104799. |
facial angiofibroma is the most predominant cutaneous manifestation of tuberous sclerosis complex (tsc), a rare autosomal dominant genetic disorder impacting the mechanistic target of rapamycin (mtor). |
2022-09-14 |
2023-08-14 |
Not clear |
| Clara Bernardelli, Eloisa Chiaramonte, Silvia Ancona, Silvia M Sirchia, Amilcare Cerri, Elena Lesm. Primary TSC2 International journal of molecular sciences. vol 23. issue 17. 2022-09-09. PMID:36077111. |
primary tsc2 cutaneous lesions are one of the hallmarks of tuberous sclerosis complex (tsc), a genetic disease in which mtor is hyperactivated due to the lack of hamartin or tuberin. |
2022-09-09 |
2023-08-14 |
Not clear |
| Alfredo Cerisola, Lucía Cibils, María Eugenia Chaibún, Virginia Pedemonte, Melania Rosa. [Tuberous sclerosis complex: diagnosis and current treatment]. Medicina. vol 82 Suppl 3. 2022-09-02. PMID:36054862. |
tuberous sclerosis complex is an autosomal dominant genetic multisystemic disorder caused primarily by mutations in one of the two tumor suppressor genes tsc1 or tsc2, resulting in increased activation of the mtor pathway. |
2022-09-02 |
2023-08-14 |
Not clear |
| Mehmet E Adin, David Durand, William B Zucconi, Anita J Huttner, Dennis D Spencer, Richard A Brone. Diagnostic and interventional radiology (Ankara, Turkey). 2022-08-23. PMID:35997478. |
for instance, it has been recently found that focal cortical dysplasia iib, tuberous sclerosis, hemimegalencephaly, and gangliogliomas are all the result of mutations of the mtor pathway for cell growth. |
2022-08-23 |
2023-08-14 |
Not clear |
| Paolo Curatolo, Nicola Specchio, Eleonora Aronic. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. The Lancet. Neurology. vol 21. issue 9. 2022-08-13. PMID:35963265. |
tuberous sclerosis complex is a rare genetic disease associated with mutations in the tsc1 or tsc2 genes, which cause overactivation of the mtor complex. |
2022-08-13 |
2023-08-14 |
Not clear |
| Paolo Curatolo, Nicola Specchio, Eleonora Aronic. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. The Lancet. Neurology. vol 21. issue 9. 2022-08-13. PMID:35963265. |
the scope for mitigation of tuberous sclerosis complex-associated symptoms has expanded, including the use of mtor inhibitors such as sirolimus and everolimus. |
2022-08-13 |
2023-08-14 |
Not clear |
| Vasiliki Karalis, Franklin Caval-Holme, Helen S Bateu. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex. Nature communications. vol 13. issue 1. 2022-08-09. PMID:35945201. |
tuberous sclerosis complex (tsc) is a neurodevelopmental disorder caused by mutations in the tsc1 or tsc2 genes, which encode proteins that negatively regulate mtor complex 1 (mtorc1) signaling. |
2022-08-09 |
2023-08-14 |
mouse |
| Pedram Argani, Andres Matoso, Aparna Pallavajjalla, Lisa Haley, Ming Tseh-Lin, Jessica Ng, C W Chow, Tamara Lotan, Rohit Mehr. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC-associated Renal Cell Carcinoma. The American journal of surgical pathology. 2022-08-08. PMID:35941720. |
over the past decade, several distinct novel renal epithelial neoplasms driven by underlying tuberous sclerosis comples (tsc)/mammalian target of rapamycin (mtor) pathway mutations have been described. |
2022-08-08 |
2023-08-14 |
Not clear |
| Paul A Roberson, Leonard S Jefferson, Scot R Kimbal. Convergence of Signaling Pathways in Mediating Actions of Leucine and IGF-1 on mTORC1 in L6 Myoblasts. American journal of physiology. Cell physiology. 2022-08-01. PMID:35912992. |
compared to leucine- and serum-deprived myoblasts, igf-1, but not leucine, promoted phosphorylation of protein kinase b (akt), tuberous sclerosis complex 2 (tsc2), and the autophosphorylation site on mtor (s2481) and also stimulated mtor kinase activity in mtor immunoprecipitated samples. |
2022-08-01 |
2023-08-14 |
Not clear |
| Rohan R Shah, W Clark Lambert, Robert A Schwart. Birt-Hogg-Dubé Syndrome: Another mTOR Phenomenon. Clinics in dermatology. 2022-07-30. PMID:35907578. |
like tuberous sclerosis, bhds's clinical features may subside with the use of oral rapamycin for mtor inhibition, a theoretical concept meriting exploration. |
2022-07-30 |
2023-08-14 |
Not clear |
| Luyang Han, Yuting Wu, Fangming Liu, Hongbing Zhan. eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest. International journal of molecular sciences. vol 23. issue 13. 2022-07-09. PMID:35805935. |
we tested the potential of eft226, a sequence-selective inhibitor of eif4a-mediated translation, in the treatment of mtor hyperactive cells caused by the deletion of tuberous sclerosis complex 1/2 (tsc1/2) or phosphatase and tensin homology (pten). |
2022-07-09 |
2023-08-14 |
Not clear |
| Femke V M Mulder, Evelien F H I Peeters, Jan Westerink, Fried J T Zwartkruis, Wendela L de Ranitz-Greve. The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry. Orphanet journal of rare diseases. vol 17. issue 1. 2022-07-08. PMID:35804402. |
the long-term effect of mtor inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the dutch tsc registry. |
2022-07-08 |
2023-08-14 |
Not clear |